Antiangiogenic therapy in pancreatic neuroendocrine tumors

Monica Capozzi, Claudia Von Arx, Chiara De Divitiis, Alessandro Ottaiano, Fabiana Tatangelo, Giovanni Maria Romano, Salvatore Tafuto

Research output: Contribution to journalReview article

Abstract

In recent years, many progresses have been pursued in the management of advanced pancreatic neuroendocrine tumor (pNET); most of them were prompted by increasing knowledge of biology of these neoplasms, including the identification of promising biological targets for therapy. PNETs belong to a group of rare neoplastic diseases. They originate from neuroendocrine system cells and are very heterogeneous regarding anatomic localization and aggressiveness. Recently, many efforts have been particularly focused on the identification of pathologic pathways and innovative drugs in order to treat patients with unresectable, metastatic disease, in progressive well-differentiated pNETs. Chemotherapy remains the mainstay of treatment of poorly-differentiated pNETs. The positive results obtained by sunitinib, a multi-targeted tyrosine kinase receptor inhibitor of vascular endothelial growth factor receptor (VEGFR) 1-3, platelet-derived growth factor receptor (PDGFR), c-kit, RET, colony stimulating factor-1 receptor (CSF-1R) and Fms-like tyrosine kinase 3 (FLT3), with direct antitumor and antiangiogenic effects, have highlighted the importance of tumor angiogenesis inhibition in controlling these tumors. Angiogenesis is a crucial process during tumor progression and plays a key role in development of metastasis.

Original languageEnglish
Pages (from-to)5025-5030
Number of pages6
JournalAnticancer Research
Volume36
Issue number10
DOIs
Publication statusPublished - Oct 1 2016

    Fingerprint

Keywords

  • Angiogenesis
  • Bevacizumab
  • Neuroendocrine tumors
  • Review
  • Sunitinib

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this